Polygenic Risk Score for glaucoma
/
The effects of glaucoma on a person’s sight can be devastating often leading to permanent loss of vision. As damage to the optic nerve is gradual, individuals may not realise they have glaucoma until loss of vision has occurred. [1]
AGRF work closely with SeonixBio, to perform Global Screening Array testing coupled with customised bioinformatics that looks at variants across the genome and informs polygenic risk scores (PRS) for glaucoma. Assessing the genetic risk of developing glaucoma will enable individuals to monitor for symptoms, detect any signs of disease early and make treatment decisions. Nick Hann, CEO explains, “Seonix began with a world-leading genetic risk prediction test for glaucoma but needed support to translate it into clinical practice. Translating a novel genetic test into the clinic demands extensive effort and a wide range of expertise across laboratory techniques, bioinformatics, and quality. AGRF has been an essential partner throughout this journey—supporting us from securing NATA accreditation to refining extraction protocols, and building the bioinformatics infrastructure for sample tracking, quality control, and reporting. Our partnership with AGRF has been instrumental in bringing our glaucoma risk prediction test to the clinic.”
By combining innovation with AGRF’s expertise, SeonixBio is enabling earlier detection and better outcomes for those at risk of glaucoma.
